Check 35,000+ stocks against 26 valuation models and 37 quality factors

Shanghai Henlius Biotech Inc (2696) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Shanghai Henlius Biotech Inc HK$62.92, price HK$58.65, upside +7.3%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · HK · Home China · ISIN CNE100003N76

SH Some data Sep 27, 2026

Shanghai Henlius Biotech Inc

2696 · HK

NeutralQuality growthThe stock looks roughly fairly valued with average quality.

·Fair value HK$62.92 · Fairly valued (+7.3%)

!Quality 58/100

!Mixed Growth (revenue 5y +62.5 %/yr)

✓Solidly profitable · 11.7% net margin (TTM)

✓Low debt · generates free cash flow

✓Ranks above peers (8/12)

!Moderate moat 57/100

!Evidence only medium, so the estimate is less certain

!The models disagree: range HK$35.53 to HK$125.02

26 models, one by oneBear HK$35.53 to bull HK$125.02 Growth analysisrevenue history, year by year Quality 58/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Shanghai Henlius Biotech Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range HK$9.70 – HK$88.70 · fair‑value band HK$35.53 – HK$125.02 · the HK$58.65 price screens below the HK$62.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Shanghai Henlius Biotech in your weekly email

Every Wednesday you see whether Shanghai Henlius Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases.

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and pediatric Crohn's disease; and HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer. The company also develops HANSIZHUANG, a serplulimab injection to treat colorectal cancer, gastric carcinoma, and limited-stage small cell lung cancer; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat of metastatic gastroesophageal junction cancer and gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX22, HLX42, HLX43, and HLX53 to treat solid tumors; HLX11 to treat breast cancer; HLX14 to treat osteoporosis; and HLX15 for multiple myeloma. The company operates in Mainland China, the Asia Pacific, North and South America, Europe, and Oceania. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical Development Co., Ltd.

Stock analysis

Shanghai Henlius Biotech Inc (2696) currently trades at HK$58.65, while our model-based Fair Value estimate is HK$62.92, so the stock looks roughly fairly valued today (gap 6.8%).

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$79.95 per share, and 8 of the 24 models we run sit above the HK$58.65 price.

Bear case: the Economic Profit group reads lowest at HK$14.70, and 16 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: HK$35.53 (bear) to HK$125.02 (bull), the price of HK$58.65 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Shanghai Henlius Biotech Inc reported revenue of 6.7B CNY in FY2025 versus 1.7B CNY in FY2021, a compound +41.1%/yr. Reported net income was 806M CNY in FY2025.

Key figures

Market cap HK$32.1B (≈ $4.1B) · P/E ratio 30.9 · P/S ratio 3.74 · Net margin 12.1% · Return on equity 21.8% · Return on assets (EBIT) 0.5% · Operating margin 14.2% · Revenue (TTM) 7.4B CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 7%, 2696 screens richer than that median.

Fair Value models

Bear HK$35.53 Fair Value HK$62.92 Bull HK$125.02

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF HK$31.03 HK$48.44 HK$102.73 72

EPV HK$13.05 HK$15.30 HK$17.25 72

Growth DCF HK$29.07 HK$56.44 HK$100.55 71

All 24 models by family

DCF Models

FCF DCF HK$31.03 HK$48.44 HK$102.73 72

Owner Earnings HK$30.82 HK$69.80 HK$148.62 67

5Y Revenue Exit HK$20.55 HK$35.03 HK$65.20 66

5Y EBITDA Exit HK$28.45 HK$50.99 HK$95.17 68

5Y P/E Exit HK$28.96 HK$65.23 HK$114.48 64

10Y Revenue Exit HK$23.35 HK$49.25 HK$64.65 63

10Y EBITDA Exit HK$29.67 HK$65.86 HK$128.41 61

10Y P/E Exit HK$30.03 HK$66.92 HK$127.14 57

Earnings-Based

Graham-Dodd HK$11.70 HK$81.61 HK$114.53 58

Lynch FV HK$42.16 HK$60.23 HK$78.30 57

PEG = 1.0 HK$42.16 HK$60.23 HK$78.30 53

EPV HK$13.05 HK$15.30 HK$17.25 72

Multiples

P/E Multiple HK$28.40 HK$37.86 HK$47.33 61

P/S Multiple HK$21.94 HK$29.26 HK$36.57 56

P/B Multiple HK$21.94 HK$29.26 HK$36.57 53

EV/EBIT HK$21.02 HK$28.44 HK$35.86 64

EV/EBITDA HK$26.47 HK$35.71 HK$44.95 66

EV/Revenue HK$14.65 HK$21.46 HK$28.26 52

Asset-Based

NCAV (Graham) HK$4.23 HK$5.67 HK$8.46 52

Growth DCF

Growth DCF HK$29.07 HK$56.44 HK$100.55 71

Rev-Margin DCF HK$22.73 HK$40.26 HK$77.05 66

Economic Profit

Residual Income HK$10.96 HK$14.70 HK$26.73 64

ROIC Compounder HK$17.49 HK$25.93 HK$32.18 68

Growth Earnings

Growth-Adj P/E HK$55.97 HK$79.95 HK$103.94 64

Open the full fair value analysis →

Notify me when 2696 reaches fair value

Put 2696 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 58/100

Of which business quality 57 · Market factors (momentum, volatility) 29

Profitability 57

Margins and returns on capital today

Quality Growth 50

Are margins and returns improving?

Cashflow 63

Earnings quality: real cash, not paper profit

Fin. Strength 49

Balance sheet, leverage, solvency risk

Investment 43

Disciplined investing over empire-building

Low Volatility 50

Calm price path (market factor)

Momentum 24

Price trend over the last 3–12 months (market factor)

52W Momentum 14

Distance to the 52-week high (market factor)

Net Issuance 79

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 92/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+16.5%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+27.5%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+62.5%

Start year 2020 (pandemic)

Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+93.5%

’17

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

+13.7%

Earnings growth per share plus dividend.

Earnings per share, growth per year+13.7%

Dividend (yield on the price)0.0%

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−157% → 12%

Growth Forecast

A lot of optimism in the price

The price assumes less growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+18.1%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+2.8%

Yearly sales growth analysts expect, extended to five years.

After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +16.1% a year for the price and +1.1% for the forecasts.

Forecast 2026 (sales)+13.9%

Forecast 2027 (sales)−0.2%

Projected 2028 (sales)+0.1%

Projected 2029 (sales)+0.3%

Projected 2030 (sales)+0.6%

Watch 2696, get fair value alerts →

Compare Shanghai Henlius Biotech Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 638 stocks

Beats the industry median on 8/12 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 58 · Top 25%

Fair Value upside +7.3% · Top 25%

Profitability

Return on equity (TTM) 21.8% · Top 25%

Return on assets 4.5% · Top 25%

Net margin (TTM) 11.7% · Above median

Operating margin (TTM) 14.2% · Above median

Growth and dividend

Revenue growth 27.3% · Top 25%

Balance sheet

Debt / equity 0.34× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 30.9× · Pricier than median

P/B 6.92× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.

P/S (TTM) 3.69× · Cheaper than median

P/FCF 31.9× · Pricier than median

EV/EBITDA 22.9× · Pricier than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)43 · sector 0

FUTURE (revenue growth)100 · sector 0

PAST (return on equity)87 · sector 0

HEALTH (low debt)83 · sector 97

DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	$527.67	$580.44	+10%
Regeneron Pharmaceuticals, Inc REGN	$752.25	$1,275	+69%
argenx SE ARGX	$959.49	$918.60	−4%
CSL Limited CSL	A$176.95	A$194.65	+10%
Samsung Biologics Co 207940	1,366,000 KRW	1,502,600 KRW	+10%
BeOne Medicines AG ONC	$360.85	$280.94	−22%
Alnylam Pharmaceuticals, Inc ALNY	$255.96	$217.88	−15%
Royalty Pharma plc RPRX	$58.21	$19.01	−67%
Celltrion, Inc 068270	177,400 KRW	74,519 KRW	−58%
WuXi Biologics (Cayman) Inc 2269	HK$53.00	HK$58.30	+10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shanghai Henlius Biotech Inc · Fair Value
HK$62.92 +7%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/2696" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Shanghai Henlius Biotech Inc · Fair Value</span><br><b style="font-size:20px">HK$62.92</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+7%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Shanghai Henlius Biotech Inc Fair Value". https://www.fairvalue-calculator.com/stock/2696

Frequently asked questions

Is Shanghai Henlius Biotech Inc (2696) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of HK$62.92 versus a price of HK$58.65, about +7% upside (fairly valued).

What is the fair value of 2696?

Our model-based fair value for Shanghai Henlius Biotech Inc is HK$62.92 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$58.65.

What is the quality score of 2696?

Shanghai Henlius Biotech Inc has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Shanghai Henlius Biotech Inc (2696)?

Our model-based price target is the fair value of HK$62.92 (as of Sep 27, 2026) from 24 valuation models. Cautious scenario HK$35.53, optimistic scenario HK$125.02. It is a calculation from audited fundamentals, not an analyst target.

What is the Shanghai Henlius Biotech Inc stock forecast for 2026?

Our models put fair value at HK$62.92, about +7% upside versus a price of HK$58.65 (fairly valued). Cautious scenario HK$35.53, optimistic scenario HK$125.02. The calculation is refreshed regularly with new filings.

What is the revenue of Shanghai Henlius Biotech Inc (2696)?

Shanghai Henlius Biotech Inc reported trailing-twelve-month revenue of about 7.4B CNY (latest available figure, as of Sep 27, 2026).

What growth is priced into Shanghai Henlius Biotech Inc (2696)?

For today's price to be fair in a discounted-cash-flow model, Shanghai Henlius Biotech Inc would have to grow free cash flow by +18.1 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +62.5 % per year. As of Sep 27, 2026.

What discount rate (WACC) does the fair value of 2696 use?

Our models discount Shanghai Henlius Biotech Inc at 9.0 %: a base by market capitalisation (mid), damped by beta 0.51, country premium for Hong Kong. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shanghai Henlius Biotech Inc that is +18.1 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.

How much growth has Shanghai Henlius Biotech Inc (2696) delivered so far?

Over the past 5 years revenue at Shanghai Henlius Biotech Inc grew +62.5 % a year. The price currently implies +18.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Shanghai Henlius Biotech Inc (2696) growing?

The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Shanghai Henlius Biotech Inc (+18.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Shanghai Henlius Biotech Inc (2696)?

The free-cash-flow yield on the price is 3.13 %: that much free cash flow Shanghai Henlius Biotech Inc produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Shanghai Henlius Biotech Inc (2696)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Henlius Biotech Inc it is HK$62.92 per share (as of Sep 27, 2026), against a price of HK$58.65. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is Shanghai Henlius Biotech Inc stock overvalued or undervalued in 2026?

As of Sep 27, 2026, 2696 trades below its calculated fair value: price HK$58.65, fair value HK$62.92, a gap of about +7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 2696?

No. The price is what the market pays today (HK$58.65); the fair value is what the company's own numbers justify (HK$62.92). For Shanghai Henlius Biotech Inc the two are HK$4.27 per share apart. That gap is exactly why we show both numbers side by side.

How much is Shanghai Henlius Biotech Inc worth?

The market values Shanghai Henlius Biotech Inc at about HK$32.1B (market capitalisation, as of Sep 27, 2026). Per share that is HK$58.65; our models calculate a fair value of HK$62.92 per share.

What do the bullish and bearish scenarios say about 2696?

Our models span a range for Shanghai Henlius Biotech Inc: cautious scenario HK$35.53, base HK$62.92, optimistic HK$125.02 per share (as of Sep 27, 2026, price HK$58.65). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 2696?

Shanghai Henlius Biotech Inc trades at a price-to-earnings ratio of 30.9 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$62.92 is built from several models across several years. Other multiples: P/B 6.9, P/S 3.7, EV/EBITDA 22.9.

How solid is the balance sheet of Shanghai Henlius Biotech Inc (2696)?

Balance-sheet figures for Shanghai Henlius Biotech Inc (as of Sep 27, 2026): return on equity 21.8%, debt of 0.34 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.

How far is 2696 from its 52-week high?

Shanghai Henlius Biotech Inc trades at HK$58.65, about 31% below its 52-week high of HK$84.45 and 14% above the low of HK$51.35 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$62.92 is for.

Which stocks are comparable to Shanghai Henlius Biotech Inc?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Shanghai Henlius Biotech Inc stock attractive at the current price?

The data as of Sep 27, 2026: price HK$58.65, calculated fair value HK$62.92 (+7%), Quality Score 58/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 2696 calculated?

We run Shanghai Henlius Biotech Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$62.92, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.7 % above its aggregate fair value. Shanghai Henlius Biotech Inc currently trades 7 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Shanghai Henlius Biotech Inc (2696)?

The closing price on Sep 30, 2026 was HK$58.65. Our model-based fair value is HK$62.92, about +7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Shanghai Henlius Biotech Inc right now?

The model range is unusually wide (HK$35.53 to HK$125.02). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.

Key figures of Shanghai Henlius Biotech Inc

How large is the market capitalisation of Shanghai Henlius Biotech Inc (2696)?

The market capitalisation of Shanghai Henlius Biotech Inc is HK$32.1B (≈ $4.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Shanghai Henlius Biotech Inc (2696)?

The price-to-sales ratio of Shanghai Henlius Biotech Inc is 3.74 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What is the net margin of Shanghai Henlius Biotech Inc (2696)?

The net margin of Shanghai Henlius Biotech Inc is 12.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Shanghai Henlius Biotech Inc (2696)?

The return on equity (ROE) of Shanghai Henlius Biotech Inc is 21.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Shanghai Henlius Biotech Inc (2696)?

On an EBIT basis the return on assets of Shanghai Henlius Biotech Inc is 0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Shanghai Henlius Biotech Inc (2696)?

The operating margin of Shanghai Henlius Biotech Inc is 14.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Shanghai Henlius Biotech Inc (2696)?

Revenue at Shanghai Henlius Biotech Inc is growing +27.3% versus a year earlier (3y avg +27.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Shanghai Henlius Biotech Inc (2696)?

Earnings per share at Shanghai Henlius Biotech Inc are growing +10.1% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does Shanghai Henlius Biotech Inc (2696) carry?

The net debt of Shanghai Henlius Biotech Inc is 2.8B CNY (fiscal year 2025, ≈ 3.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch Shanghai Henlius Biotech Inc in the live analysis

One click puts Shanghai Henlius Biotech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.